Clinical Trial Update: Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED